Skip to main content
Caplight Logo









Sibylla Biotech

Sibylla Biotech

Private
BressoHealthcare & Life Scienceshttps://www.sibyllabiotech.it/

Last Round

Series A

Oct 4, 2022

Total Funding Raised

$22.9M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Sibylla Biotech is a biotechnology company that develops small molecule therapeutics using its proprietary PPI-FIT platform to induce targeted protein degradation by interfering with protein folding pathways.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

drug discoverytargeted protein degradationprotein degradationprotein foldingAI drug discoverysmall moleculeundruggable targetsin silico drug designAI biotechcomputational biologyFIDsfolding interfering degradersPPI-FITpharmacological protein inactivationpreclinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sibylla Biotech Comparables

Compare Sibylla Biotech with similar companies based on industry and business-model similarity.

Sibylla Biotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Charm Therapeutics
83%
Peptone
83%
SyntheX
78%

Sibylla Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 4, 2022
SeedJul 1, 2019

Key People

Founding team and executive leadership

Giovanni Spagnolli

Chief Technology Officer

Executive Team

Sibylla Biotech Investors

Notable investors and investment history

Sibylla Biotech investors
InvestorRounds
Vertis SGRSeries A
Seroba Life SciencesSeries A
3B FUTURE Health FundSeries A
Indaco Venture Partners SGRSeries A
VI PartnersSeries A
V-Bio VenturesSeries A
Claris VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 17, 2026

    Monthly visitors increased 82% MoM, reaching 1K.

  • Apr 1, 2026

    Monthly visitors increased 38% MoM.

Sibylla Biotech Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Sibylla Biotech Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Sibylla Biotech's valuation, stock price, and market status.

Firmographic Details

HeadquartersBresso
Employee Range43
Year Founded2017
Last FundingOct 4, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?